Research analysts at Evercore ISI began coverage on shares of Henry Schein (NASDAQ:HSIC) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “outperform” rating on the stock.
A number of other research firms have also weighed in on HSIC. Robert W. Baird set a $95.00 price target on shares of Henry Schein and gave the stock a “buy” rating in a research report on Thursday, October 19th. Stifel Nicolaus dropped their target price on shares of Henry Schein from $89.00 to $77.00 and set a “hold” rating for the company in a research report on Tuesday, November 7th. Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Craig Hallum upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th. Finally, UBS Group restated a “buy” rating on shares of Henry Schein in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $86.21.
Henry Schein (HSIC) traded up $0.67 on Thursday, hitting $72.14. 1,421,900 shares of the company’s stock were exchanged, compared to its average volume of 1,332,700. The company has a market capitalization of $11,217.53, a price-to-earnings ratio of 20.79, a P/E/G ratio of 1.86 and a beta of 1.00. Henry Schein has a fifty-two week low of $65.28 and a fifty-two week high of $93.50. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30.
Henry Schein declared that its Board of Directors has authorized a share buyback program on Monday, September 18th that authorizes the company to buyback $400.00 million in shares. This buyback authorization authorizes the company to buy up to 6.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.
In related news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.19% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. SpiderRock Advisors LLC purchased a new stake in shares of Henry Schein in the first quarter valued at $102,000. YorkBridge Wealth Partners LLC raised its stake in shares of Henry Schein by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock valued at $104,000 after acquiring an additional 28 shares during the period. FineMark National Bank & Trust raised its stake in shares of Henry Schein by 3.3% in the third quarter. FineMark National Bank & Trust now owns 651 shares of the company’s stock valued at $106,000 after acquiring an additional 21 shares during the period. Sun Life Financial INC raised its stake in shares of Henry Schein by 8,185.7% in the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock valued at $106,000 after acquiring an additional 573 shares during the period. Finally, Global X Management Co. LLC raised its stake in shares of Henry Schein by 18.7% in the second quarter. Global X Management Co. LLC now owns 661 shares of the company’s stock valued at $117,000 after acquiring an additional 104 shares during the period. 91.69% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Henry Schein (HSIC) Receives New Coverage from Analysts at Evercore ISI” was originally posted by American Banking and Market News and is owned by of American Banking and Market News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/04/henry-schein-hsic-receives-new-coverage-from-analysts-at-evercore-isi.html.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
